Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data

T. W. Rice, T. E M R Lerut, M. B. Orringer, L. Q. Chen, W. L. Hofstetter, B. M. Smithers, V. W. Rusch, J. van Lanschot, K. N. Chen, A. R. Davies, X. B. D'Journo, Kenneth Kesler, J. D. Luketich, M. K. Ferguson, J. V. Räsänen, R. van Hillegersberg, W. Fang, L. Durand, W. H. Allum, I. CecconelloR. J. Cerfolio, M. Pera, S. M. Griffin, R. Burger, J. F. Liu, M. S. Allen, S. Law, T. J. Watson, G. E. Darling, W. J. Scott, A. Duranceau, C. E. Denlinger, P. H. Schipper, H. Ishwaran, C. Apperson-Hansen, L. M. DiPaola, M. E. Semple, E. H. Blackstone

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

To address uncertainty of whether pathologic stage groupings after neoadjuvant therapy (ypTNM) for esophageal cancer share prognostic implications with pathologic groupings after esophagectomy alone (pTNM), we report data—simple descriptions of patient characteristics, cancer categories, and non–risk-adjusted survival—for pathologically staged cancers after neoadjuvant therapy from the Worldwide Esophageal Cancer Collaboration (WECC). Thirty-three institutions from six continents submitted data using variables with standard definitions: demographics, comorbidities, clinical cancer categories, and all-cause mortality from first management decision. Of 7,773 pathologically staged neoadjuvant patients, 2,045 had squamous cell carcinoma, 5,686 adenocarcinoma, 31 adenosquamous carcinoma, and 11 undifferentiated carcinoma. Patients were older (61 years) men (83%) with normal (40%) or overweight (35%) body mass index, 0-1 Eastern Cooperative Oncology Group performance status (96%), and a history of smoking (69%). Cancers were ypT0 (20%), ypT1 (13%), ypT2 (18%), ypT3 (44%), ypN0 (55%), ypM0 (94%), and G2-G3 (72%); most involved the distal esophagus (80%). Non–risk-adjusted survival for yp categories was unequally depressed, more for earlier categories than later, compared with equivalent categories from prior WECC data for esophagectomy-alone patients. Thus, survival of patients with ypT0-2N0M0 cancers was intermediate and similar regardless of ypT; survival for ypN+ cancers was poor. Because prognoses for ypTNM and pTNM categories are dissimilar, prognostication should be based on separate ypTNM categories and groupings. These data will be the basis for the 8th edition cancer staging manuals following risk adjustment for patient, cancer, and treatment characteristics and should direct 9th edition data collection.

Original languageEnglish (US)
Pages (from-to)715-723
Number of pages9
JournalDiseases of the Esophagus
Volume29
Issue number7
DOIs
StatePublished - Oct 1 2016

Fingerprint

Esophageal Neoplasms
Neoplasms
Neoadjuvant Therapy
Esophagectomy
Survival
Adenosquamous Carcinoma
Risk Adjustment
Neoplasm Staging
Esophagus
Uncertainty
Comorbidity
Squamous Cell Carcinoma
Adenocarcinoma
Body Mass Index
Smoking
Demography
Carcinoma
Mortality

Keywords

  • cancer staging
  • chemotherapy
  • prognostication
  • radiotherapy
  • survival

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Rice, T. W., Lerut, T. E. M. R., Orringer, M. B., Chen, L. Q., Hofstetter, W. L., Smithers, B. M., ... Blackstone, E. H. (2016). Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data. Diseases of the Esophagus, 29(7), 715-723. https://doi.org/10.1111/dote.12513

Worldwide Esophageal Cancer Collaboration : neoadjuvant pathologic staging data. / Rice, T. W.; Lerut, T. E M R; Orringer, M. B.; Chen, L. Q.; Hofstetter, W. L.; Smithers, B. M.; Rusch, V. W.; van Lanschot, J.; Chen, K. N.; Davies, A. R.; D'Journo, X. B.; Kesler, Kenneth; Luketich, J. D.; Ferguson, M. K.; Räsänen, J. V.; van Hillegersberg, R.; Fang, W.; Durand, L.; Allum, W. H.; Cecconello, I.; Cerfolio, R. J.; Pera, M.; Griffin, S. M.; Burger, R.; Liu, J. F.; Allen, M. S.; Law, S.; Watson, T. J.; Darling, G. E.; Scott, W. J.; Duranceau, A.; Denlinger, C. E.; Schipper, P. H.; Ishwaran, H.; Apperson-Hansen, C.; DiPaola, L. M.; Semple, M. E.; Blackstone, E. H.

In: Diseases of the Esophagus, Vol. 29, No. 7, 01.10.2016, p. 715-723.

Research output: Contribution to journalArticle

Rice, TW, Lerut, TEMR, Orringer, MB, Chen, LQ, Hofstetter, WL, Smithers, BM, Rusch, VW, van Lanschot, J, Chen, KN, Davies, AR, D'Journo, XB, Kesler, K, Luketich, JD, Ferguson, MK, Räsänen, JV, van Hillegersberg, R, Fang, W, Durand, L, Allum, WH, Cecconello, I, Cerfolio, RJ, Pera, M, Griffin, SM, Burger, R, Liu, JF, Allen, MS, Law, S, Watson, TJ, Darling, GE, Scott, WJ, Duranceau, A, Denlinger, CE, Schipper, PH, Ishwaran, H, Apperson-Hansen, C, DiPaola, LM, Semple, ME & Blackstone, EH 2016, 'Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data', Diseases of the Esophagus, vol. 29, no. 7, pp. 715-723. https://doi.org/10.1111/dote.12513
Rice TW, Lerut TEMR, Orringer MB, Chen LQ, Hofstetter WL, Smithers BM et al. Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data. Diseases of the Esophagus. 2016 Oct 1;29(7):715-723. https://doi.org/10.1111/dote.12513
Rice, T. W. ; Lerut, T. E M R ; Orringer, M. B. ; Chen, L. Q. ; Hofstetter, W. L. ; Smithers, B. M. ; Rusch, V. W. ; van Lanschot, J. ; Chen, K. N. ; Davies, A. R. ; D'Journo, X. B. ; Kesler, Kenneth ; Luketich, J. D. ; Ferguson, M. K. ; Räsänen, J. V. ; van Hillegersberg, R. ; Fang, W. ; Durand, L. ; Allum, W. H. ; Cecconello, I. ; Cerfolio, R. J. ; Pera, M. ; Griffin, S. M. ; Burger, R. ; Liu, J. F. ; Allen, M. S. ; Law, S. ; Watson, T. J. ; Darling, G. E. ; Scott, W. J. ; Duranceau, A. ; Denlinger, C. E. ; Schipper, P. H. ; Ishwaran, H. ; Apperson-Hansen, C. ; DiPaola, L. M. ; Semple, M. E. ; Blackstone, E. H. / Worldwide Esophageal Cancer Collaboration : neoadjuvant pathologic staging data. In: Diseases of the Esophagus. 2016 ; Vol. 29, No. 7. pp. 715-723.
@article{ef6d55b3bc4d481f8840b21253bd5dff,
title = "Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data",
abstract = "To address uncertainty of whether pathologic stage groupings after neoadjuvant therapy (ypTNM) for esophageal cancer share prognostic implications with pathologic groupings after esophagectomy alone (pTNM), we report data—simple descriptions of patient characteristics, cancer categories, and non–risk-adjusted survival—for pathologically staged cancers after neoadjuvant therapy from the Worldwide Esophageal Cancer Collaboration (WECC). Thirty-three institutions from six continents submitted data using variables with standard definitions: demographics, comorbidities, clinical cancer categories, and all-cause mortality from first management decision. Of 7,773 pathologically staged neoadjuvant patients, 2,045 had squamous cell carcinoma, 5,686 adenocarcinoma, 31 adenosquamous carcinoma, and 11 undifferentiated carcinoma. Patients were older (61 years) men (83{\%}) with normal (40{\%}) or overweight (35{\%}) body mass index, 0-1 Eastern Cooperative Oncology Group performance status (96{\%}), and a history of smoking (69{\%}). Cancers were ypT0 (20{\%}), ypT1 (13{\%}), ypT2 (18{\%}), ypT3 (44{\%}), ypN0 (55{\%}), ypM0 (94{\%}), and G2-G3 (72{\%}); most involved the distal esophagus (80{\%}). Non–risk-adjusted survival for yp categories was unequally depressed, more for earlier categories than later, compared with equivalent categories from prior WECC data for esophagectomy-alone patients. Thus, survival of patients with ypT0-2N0M0 cancers was intermediate and similar regardless of ypT; survival for ypN+ cancers was poor. Because prognoses for ypTNM and pTNM categories are dissimilar, prognostication should be based on separate ypTNM categories and groupings. These data will be the basis for the 8th edition cancer staging manuals following risk adjustment for patient, cancer, and treatment characteristics and should direct 9th edition data collection.",
keywords = "cancer staging, chemotherapy, prognostication, radiotherapy, survival",
author = "Rice, {T. W.} and Lerut, {T. E M R} and Orringer, {M. B.} and Chen, {L. Q.} and Hofstetter, {W. L.} and Smithers, {B. M.} and Rusch, {V. W.} and {van Lanschot}, J. and Chen, {K. N.} and Davies, {A. R.} and D'Journo, {X. B.} and Kenneth Kesler and Luketich, {J. D.} and Ferguson, {M. K.} and R{\"a}s{\"a}nen, {J. V.} and {van Hillegersberg}, R. and W. Fang and L. Durand and Allum, {W. H.} and I. Cecconello and Cerfolio, {R. J.} and M. Pera and Griffin, {S. M.} and R. Burger and Liu, {J. F.} and Allen, {M. S.} and S. Law and Watson, {T. J.} and Darling, {G. E.} and Scott, {W. J.} and A. Duranceau and Denlinger, {C. E.} and Schipper, {P. H.} and H. Ishwaran and C. Apperson-Hansen and DiPaola, {L. M.} and Semple, {M. E.} and Blackstone, {E. H.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1111/dote.12513",
language = "English (US)",
volume = "29",
pages = "715--723",
journal = "Diseases of the Esophagus",
issn = "1120-8694",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Worldwide Esophageal Cancer Collaboration

T2 - neoadjuvant pathologic staging data

AU - Rice, T. W.

AU - Lerut, T. E M R

AU - Orringer, M. B.

AU - Chen, L. Q.

AU - Hofstetter, W. L.

AU - Smithers, B. M.

AU - Rusch, V. W.

AU - van Lanschot, J.

AU - Chen, K. N.

AU - Davies, A. R.

AU - D'Journo, X. B.

AU - Kesler, Kenneth

AU - Luketich, J. D.

AU - Ferguson, M. K.

AU - Räsänen, J. V.

AU - van Hillegersberg, R.

AU - Fang, W.

AU - Durand, L.

AU - Allum, W. H.

AU - Cecconello, I.

AU - Cerfolio, R. J.

AU - Pera, M.

AU - Griffin, S. M.

AU - Burger, R.

AU - Liu, J. F.

AU - Allen, M. S.

AU - Law, S.

AU - Watson, T. J.

AU - Darling, G. E.

AU - Scott, W. J.

AU - Duranceau, A.

AU - Denlinger, C. E.

AU - Schipper, P. H.

AU - Ishwaran, H.

AU - Apperson-Hansen, C.

AU - DiPaola, L. M.

AU - Semple, M. E.

AU - Blackstone, E. H.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - To address uncertainty of whether pathologic stage groupings after neoadjuvant therapy (ypTNM) for esophageal cancer share prognostic implications with pathologic groupings after esophagectomy alone (pTNM), we report data—simple descriptions of patient characteristics, cancer categories, and non–risk-adjusted survival—for pathologically staged cancers after neoadjuvant therapy from the Worldwide Esophageal Cancer Collaboration (WECC). Thirty-three institutions from six continents submitted data using variables with standard definitions: demographics, comorbidities, clinical cancer categories, and all-cause mortality from first management decision. Of 7,773 pathologically staged neoadjuvant patients, 2,045 had squamous cell carcinoma, 5,686 adenocarcinoma, 31 adenosquamous carcinoma, and 11 undifferentiated carcinoma. Patients were older (61 years) men (83%) with normal (40%) or overweight (35%) body mass index, 0-1 Eastern Cooperative Oncology Group performance status (96%), and a history of smoking (69%). Cancers were ypT0 (20%), ypT1 (13%), ypT2 (18%), ypT3 (44%), ypN0 (55%), ypM0 (94%), and G2-G3 (72%); most involved the distal esophagus (80%). Non–risk-adjusted survival for yp categories was unequally depressed, more for earlier categories than later, compared with equivalent categories from prior WECC data for esophagectomy-alone patients. Thus, survival of patients with ypT0-2N0M0 cancers was intermediate and similar regardless of ypT; survival for ypN+ cancers was poor. Because prognoses for ypTNM and pTNM categories are dissimilar, prognostication should be based on separate ypTNM categories and groupings. These data will be the basis for the 8th edition cancer staging manuals following risk adjustment for patient, cancer, and treatment characteristics and should direct 9th edition data collection.

AB - To address uncertainty of whether pathologic stage groupings after neoadjuvant therapy (ypTNM) for esophageal cancer share prognostic implications with pathologic groupings after esophagectomy alone (pTNM), we report data—simple descriptions of patient characteristics, cancer categories, and non–risk-adjusted survival—for pathologically staged cancers after neoadjuvant therapy from the Worldwide Esophageal Cancer Collaboration (WECC). Thirty-three institutions from six continents submitted data using variables with standard definitions: demographics, comorbidities, clinical cancer categories, and all-cause mortality from first management decision. Of 7,773 pathologically staged neoadjuvant patients, 2,045 had squamous cell carcinoma, 5,686 adenocarcinoma, 31 adenosquamous carcinoma, and 11 undifferentiated carcinoma. Patients were older (61 years) men (83%) with normal (40%) or overweight (35%) body mass index, 0-1 Eastern Cooperative Oncology Group performance status (96%), and a history of smoking (69%). Cancers were ypT0 (20%), ypT1 (13%), ypT2 (18%), ypT3 (44%), ypN0 (55%), ypM0 (94%), and G2-G3 (72%); most involved the distal esophagus (80%). Non–risk-adjusted survival for yp categories was unequally depressed, more for earlier categories than later, compared with equivalent categories from prior WECC data for esophagectomy-alone patients. Thus, survival of patients with ypT0-2N0M0 cancers was intermediate and similar regardless of ypT; survival for ypN+ cancers was poor. Because prognoses for ypTNM and pTNM categories are dissimilar, prognostication should be based on separate ypTNM categories and groupings. These data will be the basis for the 8th edition cancer staging manuals following risk adjustment for patient, cancer, and treatment characteristics and should direct 9th edition data collection.

KW - cancer staging

KW - chemotherapy

KW - prognostication

KW - radiotherapy

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84991109390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991109390&partnerID=8YFLogxK

U2 - 10.1111/dote.12513

DO - 10.1111/dote.12513

M3 - Article

C2 - 27731548

AN - SCOPUS:84991109390

VL - 29

SP - 715

EP - 723

JO - Diseases of the Esophagus

JF - Diseases of the Esophagus

SN - 1120-8694

IS - 7

ER -